ClinicaliQ Trial Snapshot
- A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) — Active Not Recruiting • Phase III • Neurology • NCT06719141.
- Trial testing a new drug (LP352) against placebo for seizures in children and adults with severe developmental epilepsy over two years.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months. Conditions: Developmental and Epileptic Encephalopathy Interventions: LP352, Placebo Lead Sponsor: Longboard Pharmaceuticals Planned Enrollment: 367 participants